key: cord-0869841-wvb9wmfv
authors: Emani, Venkata R.; Goswami, Sanjeev; Nandanoor, Dheeraj; Emani, Shaila R.; Reddy, Nidhi K.; Reddy, Raghunath
title: Randomized Controlled Trials for COVID-19: Evaluation of Optimal Randomization Methodologies - Need for the Data Validation of the Completed Trials, and to Improve the Ongoing and Future Randomized Trial Designs
date: 2020-11-12
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106222
sha: 04f075e92db5947239f79a62f106417afd41796c
doc_id: 869841
cord_uid: wvb9wmfv

During this emerging COVID-19 pandemic, initially there were no proven treatment options. With the release of randomized controlled trial results, we are beginning to see possible treatment options for COVID-19. The Recovery trials showed an Absolute Risk Reduction (ARR) in mortality by 2.8% with Dexamethasone, and the ACTT-1 trial showed that the treatment with Remdesivir reduced the Time to recovery by 4 days. The Hydroxychloroquine and Lopinavir/Ritonavir treatments did not show any mortality benefit in both the Recovery and WHO Solidarity trials. The NIH Hydroxychloroquine and Brazilian Hydroxychloroquine trials did not show any benefit for Hydroxychloroquine based on the 7-point ordinal scale outcomes. The randomization methodologies utilized in these controlled trials and the quality of published data were reviewed to examine their adaptability to treat patients. We found that the randomization methodologies of these trials were suboptimal for matching the studied groups based on disease severity among critically ill hospitalized COVID-19 patients with high mortality rates. The published literature is very limited about the disease severity metrics among the compared groups, and failed to show that the data is without fatal sampling errors and sampling biases. We also found that there is a definite need for the validation of data in these trials along with additional important disease severity metrics to ensure that the trials’ conclusions were accurate. We also propose proper randomization methodologies for the design of randomized controlled trials for COVID-19, and guidance for the publication of COVID-19 trial results.

The randomization methodologies utilized in these controlled trials and the quality of published data were reviewed to examine their adaptability to treat patients. We found that the randomization methodologies of these trials were suboptimal for matching the studied groups based on disease severity among critically ill hospitalized COVID-19 patients with high mortality rates. The published literature is very limited about the disease severity metrics among the compared groups, and failed to show that the data is without fatal sampling errors and sampling biases. We also found that there is a definite need for the validation of data in these trials along with additional important disease severity metrics to ensure that the trials' conclusions were accurate.

We also propose proper randomization methodologies for the design of randomized controlled trials for COVID-19, and guidance for the publication of COVID-19 trial results. A properly done randomized trial is always superior and provides the highest quality data. Any large, welldesigned randomized control trials should evenly distribute known and unknown factors among the intervention and control groups in order to minimize the potential for bias 1 . However, a large proportion of negative trials is a problem in critical care settings 2 , which is largely due to heterogeneous patient populations, variable presentations of disease and levels of response to treatments among these patients.

Preserving the integrity of clinical trials during the coronavirus pandemic is crucial 3 , and these trials have to be critically examined to ensure that they are yielding valid data. The NIH/NIAID's ACTT-1 and ORCHID trials are the only double-blind placebo controlled randomized trials, and all of the other trials for COVID -19 are open-label randomized controlled trials. In this manuscript, the following randomized controlled studies were reviewed to analyze the clinical impact of the treatment options.

1) The ACTT-1 trial showed no statistically significant mortality benefit for Remdesivir, but reduced the Time to recovery by 4 days 4 .

2) The Recovery trial showed an Absolute Risk Reduction (ARR) in mortality by 2.8% with Dexamethasone, and this beneficial effect was mainly seen in patients who required invasive mechanical ventilation [5] [6] [7] . This trial did not show any benefit for treatment with either Hydroxychloroquine or Lopinavir/Ritonavir 5-7 .

3) The halted ORCHID trial did not show any benefit for Hydroxychloroquine based on its 7-point ordinal scale outcomes 8,9 . 4) The Brazilian Hydroxychloroquine trial also did not show any benefit for Hydroxychloroquine based on its 7-point ordinal scale outcomes 10 .

5) The WHO Solidarity trial showed no mortality benefit using Hydroxychloroquine and Lopinavir/Ritonavir treatments 11 . These trials were launched rapidly in the middle of the pandemic, and the published findings of these trials lack important details about the disease severity among these critically ill hospitalized patients. In this review, we examined if these randomized controlled trial designs are living up to the expectations of yielding high quality data that can fully guide patient treatments.

COVID-19 is a multi-systemic disease with high mortality rates in critically ill hospitalized patients [4] [5] [6] [7] . In critically ill hospitalized patients with suspected infection, the sequential organ failure assessment (SOFA) and national early warning (NEW) score were demonstrated to be superior for the prognostication of mortality [12] [13] [14] [15] [16] [17] [18] [19] [20] . The protocol of the ACTT-1 trial adopted a daily NEW score assessment 4,21 and a recent study showed the important prognostic value of the SOFA score in predicting bad outcomes in COVID-19 patients 22 . A quick COVID-19 Severity Index (qCSI) scoring system 23 accurately predicted patients' progress to respiratory failure within 24 hours of admission using bedside respiratory examination findings which employed similar respiratory parameters as the SOFA and NEW scores. In addition to ground-glass opacities when present in the CT chest, other laboratory findings including lymphopenia particularly in young healthy adults, thrombocytopenia, hypoalbuminemia, elevated levels of D-Dimer, C-reactive protein, erythrocytic sedimentation rate (ESR), interleukin-6, procalcitonin, lactate dehydrogenase, neutrophils count are considered to be some other important indicators for COVID-19 disease severity and worse prognosis 22,24-32 .

All of the completed randomized controlled trials only randomized patients based on the respiratory support received at randomization [4] [5] [6] 10, 21, [33] [34] [35] . The examples in Table 1 illustrate the flaws in the randomization methodologies of these trials when we specifically reviewed the impact of COVID-19 disease severity. For example, a group of patients with the same baseline oxygen requirement and comorbidities can have an expected 5% to 27.6% mortality risk based on their disease severity if the SOFA score or NEW score is applied 12, 15 . Table 2 illustrates that all three of the groups that were randomized based on respiratory support, particularly the majority of patients randomized to the Oxygen group in these trials, will be at an even greater risk for the disease severity heterogenicity and unpredictability of their outcomes, creating the conditions for a very high chance of fatal sampling errors unless the disease severity metrics are assessed as part of the randomization [4] [5] [6] [7] 10 . Most importantly, the majority of deaths occurred among the patients who were randomized to the Oxygen group with 61.6% of total deaths in the Recovery-Dexamethasone trial and 56.8% of total deaths in the ACTT-1 trial 4,5 . Since the mortality rate was as high as 26.6% among all subjects in these trials, the SOFA score or NEW score mismatch (5.0% to 27.6% variability in mortality) among the groups in these randomized trials can itself create fatal sampling errors (Type I or Type II). For example, the Recovery trials were only powered for an absolute difference of 4 percentage points between the two arms 5,6,33 , and any sampling errors that would have caused 11 less deaths than what was observed in the Dexamethasone arm or 24 more deaths than what was observed in the usual care arm may result in the loss of statistical significance for Dexamethasone in the Recovery trial. These variances of 11 or 24 deaths among the two compared arms only account for 0.69% -1.51% of the total deaths (n = 1592) in the Recovery-Dexamethasone trial, which signifies the uncertainties in the conclusions reached that would have caused a high probability of Type I and/or Type II errors (a copy of the statistical analysis is enclosed).

Similarly, the same Type I or Type II fatal sampling errors can occur in all other randomized trials since the randomization methodologies were also similar.

Based on the data from Tables 1-3, we strongly believe that there is a chance for the occurrence of more than a 4% sampling error(s) in these randomized controlled trials, as these randomized controlled trials did not randomize patients based on COVID-19 disease severity for varying levels of hypoxemia (PaO2/FiO2 ratio) including the standardized metrics for disease severity in these critically ill hospitalized patients and cannot yield high quality data.

This was a double-blind placebo controlled randomized trial which evaluated the safety and efficacy of 

This was an open-labeled 2:1 randomized trial to evaluate the efficacy of low-dose corticosteroids (Dexamethasone), Hydroxychloroquine and Lopinavir-Ritonavir in the hospitalized COVID-19 patients with the primary endpoint of mortality benefit. The patients were assigned to three groups based on respiratory support received at randomization 5-7 .

They randomized 2,104 patients in the Dexamethasone trial and followed the initial goal of assigning 2,000 patients to the active drug treatment arms, but they only enrolled patients in the Hydroxychloroquine (n=1,561) and Lopinavir-Ritonavir (n=1,596 ) arms before they terminated the trials. 36, 37656 The trial enrolled a varying proportion of patients to the invasive ventilation group (4% in Lopinavir-Ritonavir,15.7% in Dexamethasone and 16.8% in Hydroxychloroquine trial) 5-7 .

This is an investigator-initiated, blinded, placebo-controlled, randomized trial evaluating Hydroxychloroquine for the treatment of hospitalized patients with COVID-19. The primary endpoint was 7point ordinal scale outcomes at day 15, and the protocol noted an initial plan to enroll 510 patients 8, 9, 35 .

However, the trial was prematurely terminated with the enrollment of only 479 patients due to a lack of benefit 8, 9, 35 . This trial was not powered for mortality benefit and the Time to recovery endpoints 38 .

This was an open-label trial (1:1:1 randomization), and patients with mild-moderate disease were allocated based on the respiratory support received at randomization. Their primary endpoint was 7-point ordinal scale outcomes, and the trial enrolled 665 patients 10 . The trial did not show any benefit with Hydroxychloroquine for the studied 7-point ordinal scale outcomes.

This is an open-label, randomized controlled trial that employed 4-arms in a 1:1:1:1 ratio randomization to either the control, the Lopinavir/Ritonavir, Hydroxychloroquine, and Remdesivir arms with all-cause mortality as the primary endpoint in the Canadian Solidarity trial. The protocol allows the individual countries participating in the trial to customize the protocol with an option to combine Interferon beta-1a with the Lopinavir/Ritonavir arm. After the recruitment of 5,500 patients as of July 1, 2020, they discontinue the trial's Hydroxychloroquine and Lopinavir/Ritonavir arms that showed no mortality benefit 11,34,39 .

3. Are the conclusions of these randomized trials with sampling errors valid in providing guidance for treatment options during this pandemic?

Many randomized controlled trials for COVID-19 were designed in the beginning of this pandemic when we did not know much about the COVID-19 disease process. Since then, we know more about the epidemiology of this disease and the disease severity indicators that can prognosticate patients who are at increased risk for worse outcomes [12] [13] [14] [15] [16] [17] [18] [19] [20] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . Based on disease prognostic markers that we know now, it is apparent that the completed randomized trials with limitations in randomization methodologies failed to show if the compared groups were matched for the important disease severity indicators to avoid sampling errors.

It is understandable that there is an urgent need to find therapeutic options that do not exist in the middle of this pandemic, but it is also equally important to plan the randomized clinical trials and then critically analyze the data with currently known prognostication markers that will be helpful to improve the analysis of data and/or protocol revisions of ongoing randomized trials and the design of any future randomized trials.

In the randomization of the ACTT-1 trial, an excess of 23 very sick patients were randomized to the placebo group on mechanical ventilation (n=22) and on high flow oxygen (n=1), and 30 additional patients with less severe disease who were on oxygen nasal canula (n=23) and not on supplemental oxygen (n=7) were randomized to Remdesivir 5 . These 53 patients' mismatches could easily have created a positive outcome for the studied endpoint, in favor of the trial drug Remdesivir (Time to recovery). Data on 42 patients from Table 2 of the publication is missing, and the allocation of these patients among Groups 4-7 is not clear.

Additionally, there is also potential for a mismatch in the other disease severity indicators (NEW score) along with a possible mismatch in Group 5 patients in the placebo arm and Group 6 patients in the Remdesivir arm with a high death/ventilation ratio, signifying multiorgan failure that could be the cause of more deaths. This variability of Remdesivir benefit among the treatment groups is suggestive of varying levels of disease severity (NEW score mismatch) rather than the potential efficacy of the studied drug in one group and the lack of efficacy for the same in the other group.

Of the randomized controlled trials with mortality outcomes, the sampling errors with limitations in randomization methodologies would have caused Type I and Type II errors in both the Recovery and WHO Solidarity trials 5,6,10,11,40 . The Recovery-Dexamethasone trial followed their goal of assigning 2,000 patients to the active drug treatment arm in order to adequately power the study 5 

Hydroxychloroquine and Lopinavir-Ritonavir studies were terminated early in both the Recovery and WHO Solidarity trials with a smaller sample size in each arm, which may have underpowered these trials unlike the Recovery-Dexamethasone trial 6,7,11 (if 28-day mortality was 20%, the allocation of at least 2000 patients to the active treatment arm would yield at least 90% power at two-sided P=0.01 to detect a proportional reduction of one-fifth 5,6,33 ).

Of the randomized controlled trials with their Time to recovery and 7-point ordinal scale outcomes, the obvious sampling biases and NEW score mismatches with suboptimal randomization methodologies may have caused Type I errors for Remdesivir in the ACTT-1 trial 4 . The Brazilian Hydroxychloroquine and the NIH ORCHID trials may have similar disease severity mismatches and they may not be powered enough like the ACTT-1 Remdesivir trial which continued beyond their initial enrollment goal in order to sufficiently power the study 38 . Underpowering of any trial with insufficient sample size may result in the trial showing lack of benefit for an intervention even when one exists 41, 42 .

Sampling bias can also occur from the timing of therapy relative to the onset of illness. For example, in the Recovery-Hydroxychloroquine trial, the median time since the onset of symptoms was 9 days in the treatment arm and usual care arm. However, in the Recovery-Dexamethasone trial, the median time since the onset of symptoms was 8 days in the treatment arm and 9 days in the usual care arm 5,6 . A relatively high toxic dose of Hydroxychloroquine was used in the Recovery-Hydroxychloroquine trial 6 , and the importance of the potential therapeutic synergistic mechanism of zinc sulfate with Hydroxychloroquine was not explored in any of the randomized controlled trials [43] [44] [45] .

The Solidarity trial platform also allows the individual countries participating in the trial to customize the protocol, which can result in high heterogenicity in the enrollment of patients in the trial that can cause difficulties in analyzing the data from heterogeneous populations and interpreting the results 46 .

Limited information exists in the current randomized trials about the monitoring for cardiac abnormalities, and specifically, how to adjudicate the cause and effect of cardiac rhythm abnormalities where a significant proportion of patients may need admission to the intensive care unit and/or may need mechanical ventilation, vasopressor use and other drugs that can prolong the QT interval with associated hypoxemia, electrolyte imbalance and/or acidosis that can potentially cause cardiac arrythmias [47] [48] [49] [50] [51] [52] [53] . The existence of these confounding factors in COVID-19 patients with severe disease and high mortality rates can independently cause cardiac arrhythmias in addition to the potential causation from the studied trial intervention.

Despite these unforeseen limitations of the randomized control trials that were not known initially, the following analysis can correct these limitations. A comprehensive review of the raw data of the whole study cohort should be performed to identify variables that can independently prognosticate worse outcomes in the study cohort. For example, in the Recovery and ACTT-1 trials, an analysis of the data can be conducted on varying levels of hypoxemia (PaO2/FiO2 ratio), disease severity using standardized metrics (NEW score, SOFA score or an equivalent metric), and biochemical markers of disease severity among patients in three respiratory support groups. For the ACTT-1 trial, the data should be adjusted for the 53 patients that were randomized against the placebo in favor of the study drug Remdesivir. Based on the analysis of the baseline disease severity data in both compared groups, a standardized statistical analysis can be done to correct for any biases that are observed in any of the randomized groups. The data should also adjust for any bias in outcomes due to delays in the starting of treatment relative to onset of symptoms to make sure both the treatment group and control group are adequately matched in each respiratory subgroup that the patient is randomized to.

The strength and limitations of randomized controlled trials were detailed in a review article, and despite their strengths, the randomized controlled trials have significant limitations, including lack of external validity in the application of the findings to populations outside the study 1 . These trials can take years to execute, and there are difficulties in performing randomized controlled trials for any infectious disease outbreaks rapidly on the basis of limited data that is available 1 . In light of limitations of the current randomized trials for COVID-19, it will be counterproductive to give more importance to these randomized control trials at the expense of other potentially useful sources of data 1 , especially during this public health emergency where observational studies can yield highly valuable information that will be helpful in designing better randomized trials for any current and/or future infectious disease pandemics. A recent meta-analysis of Chloroquine derivatives in treatment for COVID-19 showed benefit by improving clinical and virological outcomes in addition to reducing the mortality by a factor of 3, and electronic registry data analyses that did not show benefit were associated with a lack of basic treatment definitions and conflicts of interest 54 .

Multiple other observational studies have also showed a benefit of Hydroxychloroquine therapy in COVID-19 patients [55] [56] [57] [58] [59] . It is also important to understand inclusion/exclusion criteria and the modes of statistical analysis that were utilized in the observational studies of any intervention, particularly in the case of Hydroxychloroquine for COVID-19 treatment. For example, some of these observational studies that showed a lack of benefit with Hydroxychloroquine for COVID-19 treatment included patients with moderate to severe disease with clinical deterioration that were given Hydroxychloroquine and compared them with stable patients with mild disease who did not receive Hydroxychloroquine 60-63 . Additionally, some of the studies did not exclude the deaths that occurred during the first 24-48 hours of admission that would have biased findings against Hydroxychloroquine 62,63 . Among the three observational studies from the United States East Coast that did not exclude the first 24-48 hour deaths, with similar mortality rates (21.7%, 21.8% and 20.3%) in all subjects with majority of the patients receiving Hydroxychloroquine (75.9%, 76.2% and 70%), the first study performed statistical analysis among all subjects and found that the use of Hydroxychloroquine was associated with decreased in-hospital mortality 59 . The other two studies compared moderate-severe disease patients who received Hydroxychloroquine with patients with mild disease who did not receive Hydroxychloroquine and reported lack of benefit with Hydroxychloroquine for COVID-19 61, 62 .

This shows that statistical analysis of raw data by normalizing all the variables that could impact the outcomes of treatment intervention is a must.

Although a small number of randomized controlled trials were subjected to reanalysis in the published data, reanalysis of randomized controlled trial data from a sample comprising 36 articles showed that thirty-five percent of published reanalyses resulted in different conclusions compared to those of the original articles 64 . The recent retraction of the two publications pertaining to COVID-19 from highly reputed journals reinforces the benefits of careful analysis of the raw data from any clinical research study, instead of rushing it into the public domain that could potentially misguide the clinicians and have adverse effects on the society 65-68 .

The COVID-19 infection is a multi-systemic disease with the potential for a rapid deterioration of condition at any level of baseline respiratory status. In addition to baseline hypoxemia (PaO2/FiO2 ratio), the randomization should also include disease severity based on the SOFA score or NEW score (or equivalent disease severity metrics) and baseline lactic acid levels, lactate dehydrogenase, ferritin, absolute lymphocyte count, neutrophil count, renal function, liver function test including serum albumin, C-reactive protein, ESR, interleukin-6 and D-Dimer on admission and at the time of randomization. We also recommend the following:

 Any ongoing and future trials should have mortality benefit as the primary endpoint.

 Where possible, all ongoing trials should change their protocol randomization methodologies to include other disease severity indicators for randomization.

 We suggest that the sample size should be enough to adequately power the trials along the same lines as the Recovery trial ["if 28-day mortality was 20% then a comparison of at least 2000 patients allocated to active drug and 4000 to usual care alone would yield at least 90% power at two-sided P=0.01 to detect a proportional reduction of one-fifth (a clinically relevant absolute difference of 4 percentage points between the two arms)" 5, 6, 33 ].

Since the current projected mortality is less than 20%, the sample size may have to be adjusted to higher numbers to ensure a power of 90% for the trial.

All of the baseline co-morbidities, including varying levels of hypoxemia (PaO2/FiO2 ratio), and all the disease severity indicators as listed above, should be included in the published data for observational studies and even more so for randomized trials. In the case of observational cohort studies, it is essential that the study authors match both the treatment and control groups equally without any bias for baseline comorbidities and all known COVID-19 disease severity indicators, and follow standardized statistical methodologies to reach their conclusions.

The COVID-19 randomized controlled trials were rapidly completed on the basis of limited and imperfect available data about COVID-19 disease severity, and have limitations in yielding high-quality data based on the disease severity information that is currently known. Like any new disease state, we are making incremental progress in our understanding about COVID-19 disease severity, and the efficacy of therapeutic agents from all available data from various study designs including randomized controlled trials and observational studies. It is prudent to rely on the knowledge we gain from both the randomized controlled trials and non-randomized studies to make treatment decisions, and to design future randomized trials for COVID-19 or any new infectious disease emergencies. Only double-blind placebo controlled randomized trials when done with robust randomization methodologies and due process to match all treatment groups can yield valid data, that can give clinical guidance for treating COVID-19 patients. 5 24.8% Very high Recovery-Hydroxychloroquine(n=4716) 28-day mortality 6 25.6% Very high ACTT-1 Remdesivir (n=1059) No. of deaths at 14 th days 4 8.2% Very high *Recovery trials -Oxygen only respiratory support received at randomization, ACTT-1 Trial, patients in both Group 5 (supplemental oxygen) and group 6 (noninvasive ventilation or use of high-flow oxygen). 

Evidence for Health Decision Making -Beyond Randomized, Controlled Trials

Which Multicenter Randomized Controlled Trials in Critical Care Medicine Have Shown Reduced Mortality? A Systematic Review

Preserving Clinical Trial Integrity During the Coronavirus Pandemic

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. medRxiv

Statement from the Chief Investigators: no clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY. Recovery Trial website

Petal Network Website. Major US Trial Closes Showing No Benefit for Hydroxychloroquine in COVID-19

WHO. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19

Royal College of Physicians. National Early Warning Score (NEWS) 2: Standardising the assessment of acute-illness severity in the NHS. Updated report of a working party

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure

Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units

Serial Evaluation of the SOFA Score to Predict Outcome in Critically Ill Patients

The SOFA score-development, utility and challenges of accurate assessment in clinical trials

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Correction: Comparative prognostic accuracy of sepsis scores for hospital mortality in adults with suspected infection in non-ICU and ICU at an academic public hospital

A Comparison of the Quick Sequential (Sepsis-Related) Organ Failure Assessment Score and the National Early Warning Score in Non-ICU Patients With/Without Infection

SIRS and NEWS for predicting inhospital mortality and ICU admission in emergency admissions treated as sepsis

ACTT-1 Trial protocol. A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults . DMID Protocol Number

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet

Development and validation of the quick COVID-19 severity index (qCSI): a prognostic tool for early clinical decompensation

Critical care crisis and some recommendations during the COVID-19 epidemic in China

Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage. medRxiv

Early Warning Indicators of Severe COVID-19: A Single-Center Study of Cases From Shanghai, China. Frontiers in Medicine

28. zhang huizheng, wang xiaoying, fu zongqiang, et al. Potential Factors for Prediction of Disease Severity of COVID-19 Patients. medRxiv

Predictive factors of severe coronavirus disease 2019 in previously healthy young adults: a single-center, retrospective study

Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children's Hospital in

Predictors for Severe COVID-19 Infection

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY) trial protocol. Recovery trial website

Rationale and Design of ORCHID: A Randomized Placebo-Controlled Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. Annals of the

CKD and Risk of Hospitalization and Death With Pneumonia

Point of Care eGFR and the Prediction of Outcomes in Pneumonia

solidarity-clinical-trial-for-covid-19-treatments 40. ClinicalTrials.gov. Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease (ORCHID)

The Importance of Beta, the Type II Error and Sample Size in the Design and Interpretation of the Randomized Control Trial

Sample Size, and Their Reporting in Randomized Controlled Trials

Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients

Chloroquine Is a Zinc Ionophore

Zinc in Cellular Regulation: The Nature and Significance of "Zinc Signals

COVID-19: Why SOLIDARITY and DisCoVeRy trials may fail to bring informative and timely results. medRxiv

Clinical Characteristics of Covid-19 in

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study

ISARIC (International Severe Acute Respiratory and Emerging Infections Consortium)

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. The Lancet

COVID-19 in critical care: epidemiology of the first epidemic wave across England, Wales and Northern Ireland. Intensive Care Medicine

Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study

Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants

Risk Factors for Mortality in Patients with COVID-19 in New York City

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19

Reanalyses of Randomized Clinical Trial Data

Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet

RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet

Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid. medRxiv

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

A Modified Sequential Organ Failure Assessment Score for Critical Care Triage. Disaster Medicine and Public Health Preparedness